New Treatments for Lung Cancer May Reduce Fatality Rate

For the past few decades, a reduction in death rate has been seen in the US population living with one of the most common types of lung cancer, known as non-small cell lung cancer. The reduction in mortality rate may be due to the newly devised treatment approaches, says a recent study conducted by a team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The findings of the study have been published at the New England Journal of Medicine (NEJM).

Many people do not know that cancer is not a single disease. It is an umbrella term for diseases characterized by the abnormal and uncontrolled growth of cells. There are more than 200 types of cancers, each classified based on the cell that is initially affected.

The researchers focused on one of the most common types of lung cancer known as non-small cell lung cancer (NSCLC) which is characterized by uncontrolled cell growth in tissues of one or both lungs. Around 80% to 85% of the population has been suffering from NSCLC, according to an estimation published by the American Cancer Society (ACS). Whereas, the condition accounts for 76% of the cases in the United States (US) alone.

Source: Online Cancer GuuideFor the current study, the researchers collected the data from different resources including NCI’s Surveillance, Epidemiology, and End Results (SEER) cancer registry program. The team gained all the diagnoses of cancers, every type of cancer, and the rate of deaths due to cancers from SEER.

Later on, they did a comparison between NSCLC with small-cell lung cancer (SCLC), a tumor that grows and spreads faster than NSCLC. It accounts for 10% to 15% for all lung cancer diagnosis.

Before and After Analysis of Mortality Rate Among NSCLC cases

After examining the data from SEER, the team found out a significant difference among the number of deaths and rates of incidence due to NSCLC. The annual fatality rate among man was decreased from 3.2% to 6.3% from 2006 to 2013 and 2013 to 2016, respectively. Whereas, the annual incident rate was decreased by from1.9% to 3.1% from 2001 to 2008 and 2008 to 2016, respectively.

Source: NIH

The team also did a two-year survival analysis that determined a significant difference among the rate of diagnosis among people suffering from NSCLC. It has been found that 26% and 35% of the man are diagnosed with NSCLC in 2001 and 2014, respectively. The two-year survival rate was the same for the women as well.

Besides the diagnosed cases, the investigators also found out the incident rate as well as the rate of decline in the cases of deaths among both men ad women with NSCLC. The findings from the present study suggested an annual decline in mortalities and the number of incidents was 4.3% and 3.6%, respectively.

Contributing Factors that May Reduce Risk of NSCLC

  • It has been found by the research team that the newly devised treatment for the NSCLC has resulted in a decreased rate of death among the US population. The new intervention is potentially strong in targeting genetic changes caused by the tumor.
  • Another contributing factor was immunotherapy drug or immune checkpoint inhibitors that help the immune system in fighting back with tumor cells.
  • Reduced smoking was also determined as a contributing factor in reducing the risk of NSCLC.

The deputy director and the co-author of the study said: “Reduced tobacco consumption in the U.S. has been associated with a progressive decrease in lung cancer deaths that started around 1990 in men and around 2000 in women. Until now, however, we have not known whether newer treatments might contribute to some of the recent improvement”.

Source: National Jewish Health

The decline in mortality rate was noted by the researchers in 2013 when the genetic testing was started. The changes in genes caused by NSCLC were targeted by newly developed treatment approaches.

Previously, in 2012, all of the patients with NSCLC underwent genetic testing that was recommended by the National Comprehensive Cancer Network (NCCN). The genetic testing resulted in an increased mutation in Epidermal Growth Factor Receptor (EGFR) as well as in gene rearrangement by Anaplastic Lymphoma Kinase (ALK) that was targeted by the new treatment.

However, the findings of the current study suggested that the immune checkpoint inhibitors were significantly associated with the reduction in mortality rate among people living with NSCLC.

The lead researcher of the study Nadia Howlader, Ph.D., of NCI’s Division of Cancer Control and Population Sciences said:

“The survival benefit for patients with non-small cell lung cancer treated with targeted therapies has been demonstrated in clinical trials, but this study highlights the impact of these treatments at the population level. We can now see the impact of advances in lung cancer treatment on survival.”

Still, there is a need for a more evidenced-based study to find out the effects of EGFR or ALK inhibitors or other advances in therapy.

Source: Johns Hopkins Medicine
Source: Houston Methodist Leading Medicine

Leave A Reply

Your email address will not be published.